Disney vs Estée Lauder Stock, Which Is Best?
Inflation has eaten away at a lot of the money…
Sell
46
BMY Quote, Financials, Valuation and Earnings
Last price:
$56.86
Seasonality move
:
0.03%
Day range:
$56.52 - $57.67
52-week range:
$39.35 - $61.08
Dividend yield:
4.24%
P/E ratio:
--
P/S ratio:
2.44x
P/B ratio:
6.76x
Volume:
10.2M
Avg. volume:
10.4M
1-year change:
9.4%
Market cap:
$115.9B
Revenue:
$45B
EPS (TTM):
-$3.59
Analysts' Opinion
-
Consensus RatingBristol-Myers Squibb has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 17 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $60.91, Bristol-Myers Squibb has an estimated upside of 6.6% from its current price of $57.14.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $39.00 representing 31.75% downside risk from its current price of $57.14.
Fair Value
-
According to the consensus of 22 analysts, Bristol-Myers Squibb has 6.6% upside to fair value with a price target of $60.91 per share.
BMY vs. S&P 500
-
Over the past 5 trading days, Bristol-Myers Squibb has overperformed the S&P 500 by 2.34% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Bristol-Myers Squibb does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bristol-Myers Squibb has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Bristol-Myers Squibb reported revenues of $11.9B.
Earnings Growth
-
Bristol-Myers Squibb earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Bristol-Myers Squibb reported earnings per share of $0.60.
Enterprise value:
157.6B
EV / Invested capital:
--
Price / LTM sales:
2.44x
EV / EBIT:
--
EV / Revenue:
3.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
11.42x
Price / Operating cash flow:
8.40x
Enterprise value / EBITDA:
31.08x
Gross Profit (TTM):
$35.5B
Return On Assets:
-7.66%
Net Income Margin (TTM):
-15.3%
Return On Equity:
-33.18%
Return On Invested Capital:
-10.53%
Operating Margin:
18.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $46.7B | $44.9B | $47.4B | $11B | $11.9B | |
| Gross Profit | $36.8B | $34.4B | $35.5B | $8.5B | $8.9B | |
| Operating Income | $9.8B | $8B | $7.3B | $2B | $2.2B | |
| EBITDA | $19.3B | $19.6B | $5.1B | $4.9B | $4.8B | |
| Diluted EPS | $3.07 | $3.94 | -$3.59 | $0.93 | $0.60 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $34.3B | $31.4B | $26.8B | $27.6B | $28.1B | |
| Total Assets | $125.5B | $110.9B | $98.2B | $91.3B | $93.7B | |
| Current Liabilities | $20.5B | $21.5B | $18.9B | $23.5B | $22.6B | |
| Total Liabilities | $75.3B | $73.6B | $65.5B | $62.2B | $76.5B | |
| Total Equity | $50.2B | $37.3B | $32.7B | $29.1B | $17.2B | |
| Total Debt | $44.9B | $44.7B | $39.1B | $37.6B | $49.8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $13.8B | $12.9B | $15B | $4.8B | $5.6B | |
| Cash From Investing | -$1.9B | $264M | -$22.5B | -$410M | -$219M | |
| Cash From Financing | -$17.7B | -$13.6B | $7.7B | -$5.2B | -$3.9B | |
| Free Cash Flow | $12.7B | $11.7B | $13.8B | $4.4B | $5.3B | |
BMY
Sector
Market Cap
$115.9B
$49.2M
Price % of 52-Week High
93.55%
48.64%
Dividend Yield
4.24%
0%
Shareholder Yield
2.28%
-0.74%
1-Year Price Total Return
9.4%
-30.44%
Beta (5-Year)
0.449
0.754
Dividend yield:
4.24%
Annualized payout:
$2.28
Payout ratio:
-66.2%
Growth streak:
2 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$56.94
200-day SMA
Buy
Level
$49.43
Bollinger Bands (100)
Buy
Level
50.05 - 57.51
Chaikin Money Flow
Buy
Level
681.3M
20-day SMA
Buy
Level
$57.02
Relative Strength Index (RSI14)
Buy
Level
50.49
ADX Line
Sell
Level
15.98
Williams %R
Neutral
Level
-53.7285
50-day SMA
Buy
Level
$56.98
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
458.9M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2966)
Sell
CA Score
(Annual)
Level (-0.6792)
Buy
Beneish M-Score
(Annual)
Level (-2.7233)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.9398)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Stock Forecast FAQ
In the current month, BMY has received 4 Buy ratings 17 Hold ratings, and 1 Sell ratings. The BMY average analyst price target in the past 3 months is $60.91.
-
Where Will Bristol-Myers Squibb Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bristol-Myers Squibb share price will rise to $60.91 per share over the next 12 months.
-
What Do Analysts Say About Bristol-Myers Squibb?
Analysts are divided on their view about Bristol-Myers Squibb share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bristol-Myers Squibb is a Sell and believe this share price will drop from its current level to $39.00.
-
What Is Bristol-Myers Squibb's Price Target?
The price target for Bristol-Myers Squibb over the next 1-year time period is forecast to be $60.91 according to 22 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 17 analysts rate the stock a Hold.
-
Is BMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bristol-Myers Squibb is a Hold. 17 of 22 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BMY?
You can purchase shares of Bristol-Myers Squibb via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bristol-Myers Squibb shares.
-
What Is The Bristol-Myers Squibb Share Price Today?
Bristol-Myers Squibb was last trading at $56.86 per share. This represents the most recent stock quote for Bristol-Myers Squibb. Yesterday, Bristol-Myers Squibb closed at $57.14 per share.
-
How To Buy Bristol-Myers Squibb Stock Online?
In order to purchase Bristol-Myers Squibb stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
57
NARI alert for Jan 8
Inari Medical [NARI] is down 0.23% over the past day.
Buy
69
UNF alert for Jan 8
UniFirst [UNF] is up 4.97% over the past day.
Sell
31
APOG alert for Jan 8
Apogee Enterprises [APOG] is down 8.78% over the past day.
